Cargando…
The anti‐inflammatory potency of biologics targeting tumour necrosis factor‐α, interleukin (IL)‐17A, IL‐12/23 and CD20 in hidradenitis suppurativa: an ex vivo study
BACKGROUND: Biologics targeting inflammatory mediators can achieve clinical improvements in hidradenitis suppurativa (HS). However, their clinical efficacy shows great interpatient variability in daily practice. OBJECTIVES: To investigate the anti‐inflammatory potency of a selection of currently ava...
Autores principales: | Vossen, A.R.J.V., Ardon, C.B., van der Zee, H.H., Lubberts, E., Prens, E.P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850593/ https://www.ncbi.nlm.nih.gov/pubmed/30657173 http://dx.doi.org/10.1111/bjd.17641 |
Ejemplares similares
-
Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers
por: Vossen, A.R.J.V., et al.
Publicado: (2018) -
Noninvasive assessment of cytokine and antimicrobial peptide levels in hidradenitis suppurativa using transdermal analysis patches
por: Ardon, C.B., et al.
Publicado: (2020) -
Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa
por: Aarts, Pim, et al.
Publicado: (2021) -
A novel nicastrin mutation in a three‐generation Dutch family with hidradenitis suppurativa: a search for functional significance
por: Vossen, A.R.J.V., et al.
Publicado: (2020) -
Assessing Pruritus in Hidradenitis Suppurativa: A Cross-Sectional Study
por: Vossen, Allard R. J. V., et al.
Publicado: (2017)